US BioPharma Player Makes Neulasta Biosimilars Claim
Multiple Pegfilgrastim Rivals Are Competing In The US Market
The US biosimilar market for Neulasta, one of the few ‘maturing’ markets with multiple biosimilar entrants, suggests that commercial strategy more than price is of greater importance as sponsors look to prize market share from Amgen – reflecting the chasm between certain biosimilar and traditional generic markets.
You may also be interested in...
Coherus BioSciences enjoyed another strong quarter, “exceeding expectations,” management said, as the US-based player revealed where it would invest its cash pile following a round of financing in April.
Just days after it began selling the second biosimilar pegfilgrastim product in the US, and the company’s first, Coherus BioSciences’ management took to the J.P. Morgan Healthcare Conference to explain how the company is set apart from rival Mylan. Through debt financing, the California-based player has also just grabbed a further US$75 million to fuel the biosimilar’s launch.
Pfizer’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.